Sidoti Raises Earnings Estimates for USANA Health Sciences

Key Points

• Sidoti raised its USANA EPS estimate for Q3 2026 to $0.11 from $0.09 and projected $0.34 for Q1 2027 and $0.46 for Q2 2027. The company’s FY 2026 EPS guidance remains $0.76.
• USANA recently reported a quarterly loss of $0.07 per share, missing the $0.43 consensus estimate, while revenue of $223.27 million fell short of the $235 million forecast.
• Analyst sentiment remains bearish despite Sidoti’s revisions: Zacks downgraded the stock to “strong sell,” Wall Street Zen cut it to “hold,” and MarketBeat reports an average rating of “Sell.”

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Analysts at Sidoti upped their Q3 2026 earnings per share estimates for shares of USANA Health Sciences in a research note issued to investors on Thursday, August 6th. Sidoti analyst A. Lebiedzinski now anticipates that the company will post earnings of $0.11 per share for the quarter, up from their previous estimate of $0.09. The consensus estimate for USANA Health Sciences' current full-year earnings is $0.76 per share. Sidoti also issued estimates for USANA Health Sciences' Q1 2027 earnings at $0.34 EPS and Q2 2027 earnings at $0.46 EPS.

USNA has been the subject of a number of other research reports. Wall Street Zen cut shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday. Zacks Research lowered shares of USANA Health Sciences from a "hold" rating to a "strong sell" rating in a research note on Thursday. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of USANA Health Sciences in a report on Wednesday, June 24th. Two research analysts have rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of "Sell".

USANA Health Sciences Price Performance

NYSE:USNA opened at $15.43 on Monday. USANA Health Sciences has a one year low of $14.35 and a one year high of $32.32. The company has a market cap of $284.84 million, a P/E ratio of -12.75, a P/E/G ratio of 1.70 and a beta of 0.73. The firm's fifty day moving average price is $20.41 and its two-hundred day moving average price is $19.64.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of $0.43 by ($0.50). USANA Health Sciences had a negative net margin of 2.43% and a positive return on equity of 3.41%. The business had revenue of $223.27 million during the quarter, compared to the consensus estimate of $235.00 million. USANA Health Sciences has set its FY 2026 guidance at 0.760-0.760 EPS.

Hedge Funds Weigh In On USANA Health Sciences

Hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc boosted its holdings in USANA Health Sciences by 1,472.3% in the 2nd quarter. Versant Capital Management Inc now owns 1,588 shares of the company's stock valued at $34,000 after purchasing an additional 1,487 shares during the period. National Bank of Canada FI raised its position in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company's stock valued at $53,000 after buying an additional 1,201 shares in the last quarter. State of Wyoming acquired a new stake in shares of USANA Health Sciences in the first quarter valued at approximately $57,000. Tower Research Capital LLC TRC boosted its stake in shares of USANA Health Sciences by 382.5% in the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company's stock valued at $73,000 after buying an additional 1,901 shares during the period. Finally, Parallel Advisors LLC boosted its stake in shares of USANA Health Sciences by 1,354.3% in the fourth quarter. Parallel Advisors LLC now owns 3,854 shares of the company's stock valued at $76,000 after buying an additional 3,589 shares during the period. 54.25% of the stock is owned by institutional investors.

Insider Buying and Selling at USANA Health Sciences

In other USANA Health Sciences news, insider Brent Neidig sold 5,002 shares of the company's stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $19.45, for a total value of $97,288.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director John Turman Fleming sold 2,450 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $17.93, for a total value of $43,928.50. Following the transaction, the director owned 4,230 shares in the company, valued at $75,843.90. The trade was a 36.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 13,869 shares of company stock valued at $261,441 in the last ninety days. 0.82% of the stock is currently owned by corporate insiders.

Trending Headlines about USANA Health Sciences

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti raised its EPS forecasts for Q3 2026 to $0.11 from $0.09, Q1 2027 to $0.34 from $0.31, and Q2 2027 to $0.46 from $0.43. These upward revisions may be supporting a short-term rebound by suggesting analysts see potential earnings improvement beyond the current quarter. MarketBeat USANA analyst estimates
• Neutral Sentiment: Analyst sentiment has become mixed: Sidoti raised select forward estimates, while other analysts lowered near-term expectations. Investors may view the conflicting forecasts as a sign of uncertainty regarding USANA’s recovery.
• Negative Sentiment: USANA’s second-quarter earnings were far below expectations, and revenue also missed forecasts. The company now expects a full-year loss, a major deterioration from earlier expectations and the primary reason the stock has been under pressure this week. Why USANA Health Sciences Stock Plummeted This Week
• Negative Sentiment: An analyst reduced the estimate for USANA’s third-quarter EPS, indicating weaker expected profitability following the earnings miss. Q3 EPS Estimate for USANA Health Sciences Cut by Analyst
• Negative Sentiment: Zacks Research downgraded USANA from “hold” to “strong sell,” adding to the bearish analyst sentiment. Wall Street Zen also lowered its rating, reinforcing concerns about the company’s earnings outlook. Zacks Research

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company's portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA's products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source